Advertisement

Topics

Study of Depression-Ketamine-Brain Function

2014-08-27 03:13:14 | BioPortfolio

Summary

Targeting the glutamatergic system to treat depression is a new and promising strategy based on studies at the molecular, synaptic, and neuronal level but also on results of studies conducted in animal models and first clinical studies involving depressed patients.Ketamine has been proposed as a novel approach to induce rapid antidepressant response. In this pilot project the investigators aim to introduce this novel and promising approach into clinical practice. Besides the assessment of clinical efficacy, the investigators will put a special emphasis on the assessment of ketamine-associated effects on brain function using fMRI and cognitive testing.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Major Depression

Intervention

Ketamine

Location

Service de Psychiatrie Adulte, Programme dépression
Geneva
Switzerland
1207

Status

Recruiting

Source

University Hospital, Geneva

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:13:14-0400

Clinical Trials [1437 Associated Clinical Trials listed on BioPortfolio]

Ketamine Plus Lithium in Treatment-Resistant Depression

The purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for...

Ketamine and Nitroprusside for Depression

The purpose of this study is to test the effects of the medication ketamine and the medication called nitroprusside in patients with major depression. Ketamine has both good and bad effect...

Ketamine for Depression: An MRI Study

Ketamine has been shown to decrease symptoms of anxious depression quickly. This decrease has been shown to last for up to one month. MRI technology will be used before and after ketamine ...

Open Label Ketamine Treatment for Major Depressive Disorder in Veterans

Medically healthy Veterans ages 21-75 that have been diagnosed with Depression will get up to 6 treatments of Ketamine infusions, weekly. After treatment is completed, follow up will occur...

Ketamine Anesthesia for Improvement of Depression in ECT

The purpose of this prospective randomized clinical trial is to determine if patients receiving ketamine as a part of general anesthesia during electroconvulsive therapy (ECT) rather than ...

PubMed Articles [9637 Associated PubMed Articles listed on BioPortfolio]

Ketamine: Future Treatment For Unresponsive Depression?

Major Depressive Disorder (MDD) is a debilitating mental health condition which accounts for a significant portion of worldwide disability. Historically, the suggested pharmacotherapy to treat MDD hav...

Rapid Antidepressant Effect of Ketamine Correlates with Astroglial Plasticity in the Hippocampus.

Astroglia contributes to the pathophysiology of major depression and the action of antidepressant drugs through modulating synaptic plasticity; therefore, present study investigated whether fast antid...

Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.

Several pro-inflammatory cytokines have been implicated in depression and in antidepressant response. This exploratory analysis assessed: 1) the extent to which baseline cytokine levels predicted posi...

Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial.

This study was designed to examine the rapid antidepressant effects of single dose ketamine on suicidal ideation and overall depression level in patients with newly-diagnosed cancer. Forty-two patient...

Clinical and biological predictors of ketamine response in treatment-resistant major depression: Review.

The aim of this review was to determine the clinical and biological predictors of the ketamine response.

Medical and Biotech [MESH] Definitions

A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.

Depressive states usually of moderate intensity in contrast with major depression present in neurotic and psychotic disorders.

A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.

The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.

A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)

More From BioPortfolio on "Study of Depression-Ketamine-Brain Function"

Quick Search
Advertisement
 

Relevant Topics

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...


Searches Linking to this Trial